Genz 29155

Drug Profile

Genz 29155

Alternative Names: Genz29155

Latest Information Update: 22 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Amides; Benzophenones; Small molecules
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple sclerosis; Transplant rejection

Most Recent Events

  • 21 Dec 2016 Discontinued - Phase-I for Multiple sclerosis in USA (PO)
  • 21 Dec 2016 Discontinued - Preclinical for Transplant rejection in USA (PO)
  • 11 Apr 2011 Genz 29155 is available for licensing as of 31 Dec 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top